pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.

Gene Therapy 119

Gene Therapy Gene Licensing Licensing 119

BioSpace

OCTOBER 20, 2022

Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.

Gene Expression 61

Gene Expression Licensing Licensing Gene 61

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. A key natural regulator, NRF2 controls antioxidant genes’ expression.

Development 264

Development Gene Expression Licensing Licensing 264

pharmaphorum

AUGUST 2, 2021

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows that push is starting to gather momentum. Last December, Ipsen said it planned to spend $3.6

Gene Expression 105

Gene Expression Gene Licensing Licensing 105

pharmaphorum

JUNE 27, 2022

The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. The delivery vector – an AAV8 capsid – is designed to allow gene expression directly in target tissues like skeletal muscle.

Gene Therapy 52

Gene Therapy Gene Gene Expression Trials 52

pharmaphorum

MAY 26, 2022

Gümrükcü is a specialist in gene expression profiling in stem cells, and has been working on ways to deliver stem cell transplants to treat cancer without the need for high-dose induction chemotherapy to destroy the patient’s bone marrow. .” ” If convicted, they face mandatory life in prison or the death penalty.

Gene Expression 105

Gene Expression RNA Containment Licensing 105

XTalks

JUNE 17, 2022

Olumiant is a Janus kinase (JAK) inhibitor that was first discovered by Incyte and then licensed to Eli Lilly. It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of gene expression.

FDA Approval 97

FDA Approval Gene Expression Cosmetics Trials 97